Donald Richards, MD
Medical Oncology · Tyler, TXNPI 1659313559
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,408 of the $38,277 with a category attached, or 61.2%. 36 manufacturers reported payments, led by Seagen Inc. at 25.6% of the total. Reporting peaked in 2020 at $15,566 and has fallen 83.4% since, to $2,578 in 2025.
Across 142 payments — averaging $269.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$10K
- Ipsen Biopharmaceuticals, Inc$8K
- AstraZeneca$4K
- Jazz Pharmaceuticals Inc.$3K
- Taiho Oncology, Inc.$2K
- Janssen Global Services, LLC$2K
- plus $9K from 30 others
Across 3,198 payments — averaging $3555.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$2.5M
- Seagen Inc.$1.1M
- Genentech, Inc.$1M
- AstraZeneca$986K
- Eli Lilly$810K
- Mirati Therapeutics, Inc.$685K
- plus $4.3M from 35 others
What the payments were for
- Consulting fees$23,40861%
- Speaking & faculty fees$8,89523%
- Travel & lodging$1,3594%
- Food & beverage$4,16111%
- Education$4551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 7 | $9,781 |
| Ipsen Biopharmaceuticals, Inc | 13 | $8,380 |
| AstraZeneca | 12 | $4,089 |
| Jazz Pharmaceuticals Inc. | 2 | $2,871 |
| Taiho Oncology, Inc. | 6 | $2,192 |
| Janssen Global Services, LLC | 1 | $1,980 |
| Array Biopharma Inc | 8 | $1,675 |
| Bayer | 2 | $1,645 |
| Incyte Corporation | 3 | $1,585 |
| Aadi Bioscience, Inc. | 1 | $1,000 |
| Amgen | 3 | $535 |
| Johnson & Johnson(2 entities) | 8 | $381 |
| AbbVie | 14 | $352 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $214 |
| Tempus AI, Inc | 14 | $190 |
| Exelixis Inc. | 3 | $146 |
| Galvanize Therapeutics, Inc | 1 | $144 |
| Novartis | 7 | $136 |
| Genentech USA, Inc. | 1 | $121 |
| Gilead(2 entities) | 5 | $115 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Myriad Genetic Laboratories, Inc. | 1 | $98 |
| Bristol Myers Squibb | 1 | $77 |
| Tesaro, Inc. | 1 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Pfizer | 2 | $42 |
| Sobi, Inc | 2 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Immunocore Limited | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Sanofi | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $27 |
| Iovance Biotherapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONIVYDE$8,135
- TAGRISSO$3,575
- ZANIDATAMAB$2,790
- Lonsurf$2,149
- BRAFTOVI$1,575
- FYARRO$1,000
- PEMAZYRE$970
- Stivarga$900
- Nubeqa$745
- Prolia$319
- ALIYA SYSTEM$144
- NEUWAVE Flex Microwave Ablation System$122
- ROZLYTREK$121
- LYNPARZA$121
- SOMATULINE DEPOT$120
- IMFINZI$119
- CALQUENCE$106
- Cabometyx$103
How this compares
$38,277 in reported general payments places this provider in the 75th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 53 | $840,192 |
| WeliregBelzutifan | 14 | $394,914 |
| Lenalidomide | 16 | $306,926 |
| NinlaroIxazomib Citrate | 15 | $195,355 |
| JakafiRuxolitinib Phosphate | 11 | $193,384 |
| XtandiEnzalutamide | 12 | $172,859 |
| Abiraterone Acetate | 55 | $90,253 |
| EliquisApixaban | 43 | $28,783 |
| XareltoRivaroxaban | 12 | $7,240 |
| Letrozole | 227 | $6,009 |
| Erlotinib Hcl | 14 | $4,410 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 86 | $3,067 |
| ValacyclovirValacyclovir Hcl | 14 | $1,023 |
| Potassium Chloride | 61 | $944 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $77 | $840,19253 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $57 | $195,35515 claims |
| Incyte CorporationJakafi | $1,585 | $193,38411 claims |
| Astellas Pharma US IncXtandi | $38 | $172,85912 claims |
| PfizerEliquis | $42 | $28,78343 claims |
| Johnson & JohnsonXarelto | $381 | $7,24012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Tyler
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.